Brookdale Senior Living Inc. (NYSE:BKD) just moved higher on the value chain in the senior living segment, following the announcement of its $1.4 billion purchase of stocks inEmeritus Corp. (NYSE:ESC). The overall value of the merger is at $2.8 billion, which includes debt. The per share rate that BKD offered Emeritus shareholders is 33% higher than the day’s price, paying $28.56 on per share. Brookdale Senior Living, Inc. (NYSE:BKD) stock opened at $31.50 in last session, and closed at $30.55, while the day range of BKD stock is $30.49-$32.28.The stock showed a positive weekly performance of 33.38%.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened at $5.21, in last session and closed at $6.00, by gained 15.38%.The 52 week range was $0.19-$6.09.Company’s market capitalization is $382.14 million.
Pharmacyclics, Inc. (NASDAQ:PCYC) on Feb. 20 reported financial results and recent developments for the quarter and year ended December 31, 2013. Total revenue for the quarter ended December 31, 2013 increased 113% to $123.6 million, from $58.0 million for the quarter ended December 31, 2012. Non-GAAP net income reported for the quarter ended December 31, 2013 was $73.9 million, or $1.00 and $0.95 net income per basic and diluted share, respectively, compared to non-GAAP net income of $46.2 million, or $0.66 and $0.62 net income per basic and diluted share, respectively for the quarter ended December 31, 2012. Pharmacyclics, Inc. (NASDAQ:PCYC) stock gained 6.26% and finished the last session at $151.61.The EPS of the stock remained 0.54.Company’s market capitalization is $11.09 billion.
Horizon Pharma (NASDAQ:HZNP) had its price objective raised by R. F. Lafferty from $11.00 to $13.00 in a research report released on Wednesday morning, Analyst RN reports. R. F. Lafferty currently has a buy rating on the stock. Horizon Pharma Inc (NASDAQ:HZNP) stock opened the session at $11.18, and closed the session at $12.04. The 52 week range of the HZNP stock remained $1.97-$12.25 and the day range was $11.11-$12.25.